Ocymen: a compound from fifteen profiles that is not listed in the pharmacy register

• In the pharmacy register. Not listed in any of the 85 strains, although profile databases mention it in 15 of them. This is the content of this page, not a gap.
• Evidence. 1 work from 2023 to 2023, all on animals or in cell culture, none on patients using the herb.
• Temperature. 177.0 °C, with the measurement condition determining whether the number means anything.
• What we do not provide. Percentage share in the profile, as the denominator in sources varies and the numbers are not comparable between strains.

What is ocymen and where does it occur outside of cannabis?

Ocymen is a volatile monoterpene with the formula C10H16 and a molecular weight of 136.23, recorded in the PubChem database under number 18756 as beta-ocymen. Outside of cannabis, it has been noted in common hop and jaborandi, and the FAO and WHO expert committee lists it under number 1338 in the class of flavoring substances.

In terms of structure, it is an open-chain hydrocarbon, without a ring like limonene and pinene. The systematic name is 3,7-dimethyl-1,3,6-octatriene, and the CAS number is 13877-91-3. The profile databases used by this cluster simply write “ocymen” and do not specify the isomer, while the PubChem record and the only work in our evidence base concern the beta form. This is not a minor editorial detail: the alpha and beta forms have the same mass but are separate compounds, and the notation without the Greek letter does not allow determining which one is referred to.

The same record describes the pure compound as a colorless or straw-colored liquid with a warm, herbal scent, insoluble in water and soluble in oils. From there comes the only physical number we have for ocymen: a boiling point of 177 degrees Celsius, provided by the expert committee on food additives.

The occurrence outside of cannabis is described sparingly by the PubChem database. It mentions common hop (Humulus lupulus) and jaborandi (Pilocarpus microphyllus), then adds a formula for other organisms for which data is available. The list of species has not been closed, so it cannot be read how common this compound is in the plant world. The entry in the class of flavoring substances indicates that the food industry knows this ingredient as permitted for use, which is information about trade, not about its effect on humans.

How long does ocymen take to reach the body and how long does it stay?

It is unknown. No one has measured how much ocymen from the herb enters the blood after vaporization or how quickly the body eliminates it. The public database provides one number for this compound, the boiling point of 177 degrees Celsius, and even that does not indicate at what pressure it was measured.

The route of administration determines the course more than the strain itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the material first passes through the intestine and liver, so the first sensations are waited for from half an hour to two, and the episode lasts six, sometimes eight hours. This is where the most common mistake in oral administration comes from: those who think nothing is happening after thirty minutes and take another dose will receive both doses at once. The above ranges describe the route of administration, not this strain; pharmacokinetic studies for a single cultivar have not been published.

The number 177 degrees comes from the record of the FAO and WHO expert committee and in our data carries the designation of measurement without specified pressure. The distinction is important: under reduced pressure, the same substance boils at a lower temperature, so the notation without pressure cannot be compared with values measured under room conditions. The field for boiling point at atmospheric pressure has therefore been left empty for ocymen.

The boiling point describes the moment when a pure liquid begins to boil in a laboratory vessel. It is not a setting of the device, and we do not provide any settings or methods of taking the material here. We also do not have data on how much ocymen remains in the vapors after heating the herb: no source in this project measures that.

What have studies shown about the effects of ocymen?

One work and one test tube. In the evidence base of this cluster, ocymen has exactly one study: a cell culture with the Leishmania parasite and macrophages, published in 2023. There is no work on rodents, no work on humans, so no results can be transferred to patients.

The result of this work in the record of our evidence base reads as follows. Beta-ocymen destroyed amastigote forms of Leishmania inside macrophages at an effective concentration of 0.89 micromoles, disrupting the permeability of the parasite’s membrane; increased the secretion of tumor necrosis factor alpha, nitric oxide, and reactive oxygen species, while decreasing interleukins 10 and 6. The authors called the result promising and indicated animal studies as a step yet to be taken.

For a person taking herb from the pharmacy, nothing direct follows from this. The effective concentration is established in a vessel where the researcher selects the dose around the cells, not in the body, to which the component would first have to reach in any amount. The caveat about animal studies as a step yet to be taken actually comes from the authors themselves, so the next step in this line of research is still ahead, and there are more steps between the test tube and the patient.

What has not been shown about ocymen?

There are no studies of ocymen in humans or animals. The only work concerns cell culture and a parasite, not humans, and the authors themselves indicate animal studies as a step before them. Claims about antiviral and antibacterial effects in humans have no support in it.

The lack of studies in humans means exactly what it says: there is no measurement of dose, no measurement of time, and no described patient. In the only work we have, the compound was applied directly to cells in a vessel, at a concentration chosen by the researchers. Between such a setup and inhaling vapors of the herb lies the entire path, which has not been measured for ocymen: how much of it passes into the blood, how quickly the liver eliminates it, what happens to the rest.

Claims circulating about this compound online have no support in this work, and our evidence base does not provide any other. This especially applies to claims about antiviral or antibacterial effects in humans: a study on a parasite in cell culture is not about that, and translating such a result to a person taking the drug would be an abuse, not a shortcut.

Separately, there is the matter that is rarely written about: it is not even certain that a given strain contains this compound. Of the two profile databases used in this project, one mentions ocymen, while the other is silent about it in every description. The statement about what has not been shown therefore also includes composition: evidence of action and evidence of presence are equally poor here.

We write this directly because such a record is rare. Pages about strains usually mention terpenes and immediately assign them effects, without showing what that assignment is based on. Here it stands on one position from the test tube, and that is the whole answer.

What adverse effects have been reported after ocymen?

None. For ocymen itself, there is not a single report in this database, as safety reports describe the medicinal product, not a single component of the profile. The only work measured the fate of a parasite in cell culture, not tolerance in humans, so it says nothing about symptoms.

Reports of adverse effects are collected for medicinal products with a batch number, not for the name of a strain, so the following concerns cannabis herb as a group of raw materials. The most commonly reported are dry mouth, red eyes, and increased heart rate. Less frequently described are dizziness upon rapid standing, daytime drowsiness, and transient worsening of short-term memory, as well as anxiety increasing with dosage. A separate matter is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for cannabis herb in Poland do not separate them by individual products.

The general belief that vapors of volatile compounds in high concentrations can irritate the respiratory tract and skin comes from areas other than this evidence base, and for ocymen, we do not have such a measurement and do not provide it second-hand. The aerosol inhaled from the herb is, after all, a mixture in which this compound never stands alone: in descriptions where it has been mentioned, it most often neighbors with myrcene or caryophyllene. Therefore, no symptom could be attributed to it alone even if reports existed.

Which strains from Polish pharmacies have ocymen as the leading terpene?

None. The pharmacy register used by this cluster names the leading terpene only by six names, and ocymen is not among them, so none of the one hundred forty-one positions indicates it as leading. In the profile descriptions, however, this compound appears in fifteen strains.

The six names from the pharmacy dictionary are myrcene, caryophyllene, limonene, terpinolene, pinene, and nerolidol. Ocymen is not in this dictionary, so the question of dominance does not have a positive answer here, and it cannot be created by stretching the data. Among the eighty-five strains of the cluster, the leading terpene is most often caryophyllene, in thirty strains, followed closely by myrcene, in twenty.

The fifteen strains to which the profile source assigns ocymen include twenty-two pharmacy positions out of one hundred forty-one. The register assigns them four different leading terpenes: terpinolene and myrcene five strains each, caryophyllene three, pinene two. Where the profile source sees ocymen, the pharmacy register sees something else, and the table below compares one with the other precisely to avoid obscuring this difference.

The complete list of pharmacy positions is maintained by the list of strains available in Polish pharmacies. Herb dispensed by a doctor’s prescription is a different category of product than cannabis herb in retail and the two lists should not be confused.

How do we know that a strain contains ocymen at all?

From one source and therefore with a caveat. Ocymen is mentioned only by the database budcare.pl, in twenty of its one hundred forty-three descriptions with a detailed profile. The second database, medweed.pl, does not mention it even once in sixty-five descriptions, so the presence of the compound is based here on a single record.

Within this one source, the record is also not stable. Ghost Train Haze has two descriptions there, and ocymen is in one of them. Island Sweet Skunk has five descriptions, the compound appears in four, while the fifth lists five other names. These are not different strains, but separate entries for the same strain, describing different registration positions.

The second reason for caution is numerical. The sums of shares given in these twenty descriptions yield thirteen different values, from 65 to 101, although the components of one position cannot exceed one hundred. Since the sum sometimes does not even close to two-thirds of the scale, and sometimes exceeds it, the denominator remains unknown. Therefore, we do not place any share number next to the name of the compound, although the source provides it.

The third thing is the name itself. The source writes “ocymen” without the Greek letter, while the record in PubChem and the only evidence work concern the beta form. From the strain description, it cannot be read whether it refers to the same isomer, and we do not assume that from the source. The sixteenth name under which this source places ocymen is Bakerstreet and has no equivalent in our pharmacy register, so it did not enter the above comparison.

Does the presence of ocymen in the profile say anything about the aroma or effects of the strain?

No, it does not. The aroma and effect labels are assigned by the source to the entire entry, never to a single compound, and in each of these twenty descriptions, ocymen stands next to two to eight other terpenes. From such a record, it is impossible to extract the share of a single substance in the aroma.

In the twenty descriptions with ocymen, the most common aroma labels are peppery and pine, with nine entries each, followed by citrus and mint, with eight each. The range is so wide that it does not form any aroma profile assigned to this compound. Pure beta-ocymen is described by the expert committee as a liquid with a warm, herbal scent, but that is the characteristic of a substance isolated in the context of food aromas, not a description of the aroma of the herb.

Similarly, the situation stands with the effect label. The database assigns it to each entry as a commercial classification, and among the twenty descriptions with ocymen, fourteen carry the stimulating label. This is a sales record, not a research result, and there is no work behind it about this compound in humans. Our evidence base has one position for ocymen, described above, and it says nothing about sensations.

Co-occurrence, however, says something different than is usually written. In seventeen of the twenty descriptions, ocymen neighbors with myrcene, in fifteen with caryophyllene, in thirteen with terpinolene. A strain with ocymen is therefore primarily a strain whose profile has been described multi-componentially, not a strain distinguished by a single component.

Frequently asked questions about ocymen

Does any strain from a Polish pharmacy have ocymen as the leading terpene?

None. The pharmacy register on which this cluster stands describes the leading terpene only by six names, and ocymen is not among them. The compound appears, however, in the profile descriptions of fifteen strains from the same register.

How many studies on ocymen does the evidence base of this cluster have?

One. It is a work from 2023 on cell culture, in which beta-ocymen acted on a parasite inside macrophages. There is not a single study on animals and not one involving humans.

Is the boiling point of ocymen a setting for the vaporizer?

No. One hundred seventy-seven degrees Celsius is the boiling point of the pure compound read from the public database, additionally without specified measurement pressure. It is not a recommendation regarding the device, and we do not provide such settings here.

Does ocymen have antiviral or antibacterial effects?

This has not been demonstrated in humans. The only work in this database concerns a parasite in cell culture, not an infection in a patient, and its authors indicate animal studies as a step yet to be taken.

Why do you not provide how much ocymen is in the strain profile?

Because the denominator is unknown. The sums of shares given in descriptions with this compound yield thirteen different values, from 65 to 101, although the components of one position cannot exceed one hundred. A number without a denominator looks like a measurement, but it is not.

Does the aroma of the strain reveal the presence of ocymen?

No. Aroma labels in profile databases describe the entire entry, not a single component, and in descriptions with ocymen, they spread widely: from peppery and pine to citrus and mint.

Cannabis herb is a pharmaceutical raw material dispensed by a doctor’s prescription in the Rpw category, and advertising such products directed to the public is prohibited. The material is for informational purposes and does not replace the advice of a doctor or pharmacist. The editorial text was prepared by the team ubucha.pl.